Bipolar Mania: Improving Recognition, Diagnostic Accuracy, and Evidence-Based Treatment
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, October 28, 2009Click here to access additional resources mentioned in the live broadcast.
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, October 28, 2010
Note: Credit Is No Longer Available
 | Roger S. McIntyre, MD, FRCPC (Moderator) University of Toronto University Health Network Toronto, ON Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA) Chicago, IL Clinical Professor, Department of Psychiatry and Neurosciences University of California School of Medicine Riverside, CA |
 | Paul E. Keck, Jr., MD President-CEO, Lindner Center of HOPE Professor of Psychiatry & Behavior Neuroscience University of Cincinnati College of Medicine Cincinnati, OH |
 | Gary S. Sachs, MD Co-Director, Bipolar Clinic and Research Program Massachusetts General Hospital Founder, Concordant Rater Systems Associate Professor of Psychiatry Harvard Medical School Boston, MA |
| Amit Anand, MD (Content/Peer Reviewer) Professor of Psychiatry and Radiology Indiana University Bloomington, IN |
A cardinal feature of bipolar disorder is the irregular recurrence of alternating abnormal mood states including
depression, mania, and mixed states. Mania is frequently revealed retrospectively; patients are often not accurate in
their recall of the severity and duration of symptoms, which can add further complexity to diagnosis. Symptoms of
mania can include racing thoughts, pressured speech, irritability, lack of sleep, sexual preoccupation, excessive energy,
and expansive mood, all of which can lead to problems at home, work, or school. Symptoms vary across individuals
and disease course, and are often accompanied by comorbidities, all of which can pose diagnostic challenges.
Delayed treatment has been shown to be associated in some cases with increased hospitalizations, greater risk of
suicide, emergence of comorbid conditions, and global impairment. Once stabilized, maintenance treatment—
pharmacotherapy, patient and family education, and psychosocial support—must be considered to prevent relapse,
achieve better stability of mood, and improve function. In this interactive and evidence-based neuroscienceCME Live
and On Demand activity, the expert faculty will translate the evidence to improve outcomes in patients through better
recognition, diagnosis, and treatment of bipolar mania.
Chengappa KNR, Goodwin GM. Characterizing barriers, challenges, and unmet needs in the management of bipolar disorder. Bipolar Disord 2005;7(Suppl 1):5-7.
To improve competencies of clinicians managing patients with bipolar mania through better assessment, diagnosis, and treatment of the disorder.
At the end of this CE activity, participants should be able to:
- Integrate expert consensus, evidence base, structured interview, and assessment tools to accurately diagnose bipolar mania.
- Compare and contrast available agents for the acute management of bipolar mania in terms of efficacy and tolerability.
- Utilize guideline-based recommendations to develop individualized, multimodal treatment plans for the long-term management of patients with bipolar mania.
Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc., in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in mental health.
CME Credit (Physicians):
Indiana University School
of Medicine is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical
education for physicians.
Indiana University School of Medicine designates this
educational activity for a maximum of 1.0 AMA PRA
Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the
activity.
CNE Credit (Nurses):
This continuing nursing education
activity was approved by the New York State Nurses
Association, an accredited approver by the American Nurses
Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7ZDSRD-10. 1.0 contact
hours will be awarded upon successful completion.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content.
(1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program
has been approved for 1 hour by the Commission for Case
Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-09-025-L01-P (live presentation)
376-999-09-025-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Activities tab–requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4–6 weeks to all who successfully complete
these requirements. This website supports all browsers except
Internet Explorer for Mac. For complete technical requirements
and privacy policy, visit www.neurosciencecme.com/technical.asp.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
Disclosure Declaration
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
Dr. McIntyre has disclosed that he receives grants/research support from AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Janssen-Ortho, Inc, the National Alliance for Research on Schizophrenia and Depression (NARSAD), Shire Pharmaceuticals, and the Stanley Medical Research Institute. He serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, The France Foundation, GlaxoSmithKline, H. Lundbeck A/S, Janssen-Ortho Inc., Organon Pharmaceuticals USA Inc., Pfizer Inc., Schering-Plough Corporation, Shire Pharmaceuticals, Solvay Pharmaceuticals, Inc., and Wyeth Pharmaceuticals. He serves on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Eli Lilly and Company, H. Lundbeck A/S, Janssen-Ortho Inc., and Wyeth Pharmaceuticals.
Dr. Keck has disclosed that he serves as a consultant to GlaxoSmithKline, Organon Pharmaceuticals USA Inc., Pfizer, Inc., and Schering-Plough Corporation.
Dr. Sachs has disclosed that he receives grant support from GlaxoSmithKline, the National Institute of Mental Health, and Repligen Corporation. He serves as a consultant to, or on the advisory boards of, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Concordant Rater Systems, Eli Lilly and Company, GlaxoSmithKline, Janssen, L.P., Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Repligen Corporation, Sanofi-aventis, Schering-Plough Corporation, Sepracor Inc., and Wyeth Pharmaceuticals.
Dr. Anand has disclosed that he has received honoraria from Pfizer Inc. as a consultant, and has received research grants from Eli Lilly and Company and AstraZeneca Pharmaceuticals LP as an independent investigator.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Indiana University School of Medicine, CME Outfitters, LLC, the faculty, Bristol-Myers Squibb Company, and Otsuka America Pharmaceutical, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-064-102809-08
